glp-1 obesity drug news today oct 2025 Genetics: How Genes Affect Appetite, Semaglutide, and Tirzepatide Response The GLP-1 Access Gap: Mapping

The drug performed better on all secondary endpoints as well, including a greater percentage of people losing at least 15% of their weight (roughly a third of those on the highest dose achieved this)

While adipose tissue (fat) is the preferred source, the body will also break down skeletal muscle for amino acids if specific preservation signalsnamely dietary protein and mechanical stressare absent

Mathieu C, Dandona P, Gillard P et al (2018) Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 Study): 24-week results from a randomized controlled trial

The relative risks of complications, including progression of CKD to end-stage kidney disease (ESKD), CVD and mortality, are increased with both reduced eGFR and elevated UACR levels [1]